옵션 체인은 다양한 행사가격과 만기일에 대한 Vigil Neuroscience의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Vigil Neuroscience에 대한 시장 심리를 평가합니다..

Vigil Neuroscience (NASDAQ:VIGL) 주식, 옵션 체인

VIGIL NEUROSCIENCE INC

Vigil Neuroscience

Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.

Fear and Greed

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

VIGL

CNN 머니 공포·탐욕 지수는 전반적인 시장 심리에 일부 개선을 보였으며, 지수는 목요일(22일)에 &#34;탐욕&#34; 영역에 머물렀다.미국 주식은 목요일에 혼조세로 마감했으며, 나스닥 종합지수는 세션 중 50포인트 이상 상승했다.

긍정적 경제지표 속 나스닥 50p 이상 상승: 투자 심리 개선, 공포 지수는 여전히 &#39;탐욕&#39; 영역

Vigil Neuroscience Inc

President&nbsp;Donald Trump&nbsp;announced on Friday that&nbsp;United States Steel&nbsp;Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) and&nbsp;Nippon Steel&nbsp;will enter a partnership, following the Japanese company&#8217;s blocked acquisition attempt due to <a href="https://www.benzinga.com/markets/equities/25/05/45510183/nippon-steel-pledges-14-billion-including-new-us-mill-to-win-trumps-approval-for-us-steel-deal-report">security concerns. </a>
The Details: Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/114558783827880495">revealed on </a>Truth Social that the collaboration is projected to generate 70,000 jobs and inject $14 billion into the U.S. economy. The headquarters of U.S. Steel will stay in Pittsburgh, with most investments occurring in the next 14 months, <a href="https://www.cnbc.com/2025/05/23/trump-greenlights-nippon-merger-with-us-steel.html">according to</a> CNBC. 
Following the announcement, U.S. Steel&#8217;s stock soared over 20%, closing at $52.17 per share.
Earlier this year, President&nbsp;Joe Biden&nbsp;blocked Nippon Steel&#8217;s $14.9 billion acquisition of U.S. Steel, citing risks to critical supply chains. 
In April, Trump initiated&nbsp;a new review of the&nbsp;acquisition, instructing&nbsp;the Committee on Foreign Investment&nbsp;in the United States to&nbsp;assess the situation further.
Why It Matters: The partnership between&nbsp;U.S. Steel and Nippon Steel&nbsp;marks a significant shift in the U.S. steel industry landscape. The alliance is poised to bolster the domestic steel sector and enhance economic growth. 
The decision to keep U.S. Steel&#8217;s headquarters in Pittsburgh underscores Trump&#8217;s commitment to maintaining a strong industrial presence in the region.
See Also: <a href="https://benzinga.com/25/05/45580298/trumps-big-beautiful-bill-strips-key-retirement-benefits-from-federal-workers-in-razor-thin-house-vote" target="_blank" rel="noreferrer noopener">Trump&#8217;s &#8216;Big, Beautiful&#8217; Bill Strips Key Retirement Benefits From Federal Workers In Razor-Thin House Vote</a>
Furthermore, the partnership reflects a strategic move to balance national security concerns with economic interests. President Biden&#8217;s initial block on the acquisition highlighted the importance of safeguarding critical supply chains. 
However, Trump&#8217;s decision to approve the partnership <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44847636/with-nippon-deal-in-trumps-court-jpmorgan-turns-cautious-on-us-steel">suggests a willingness</a> to explore alternative avenues for collaboration that align with national security priorities.
In the lead-up to this decision,&nbsp;<a href="https://www.benzinga.com/markets/equities/25/05/45510183/nippon-steel-pledges-14-billion-including-new-us-mill-to-win-trumps-approval-for-us-steel-deal-report">Nippon Steel pledged $14 billion</a>&nbsp;to U.S. Steel&#8217;s operations, including up to $4 billion for a new steel mill as part of its efforts to secure approval from the Trump administration for its acquisition bid. 
X Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, United States Steel shares ended Friday&#8217;s session up 21.6% at $52.17 and continued to climb in extended trading. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://benzinga.com/markets/cryptocurrency/25/05/45579297/peter-schiff-says-a-president-shouldnt-sell-white-house-tours-and-pocket-the-proceeds-as-t" target="_blank" rel="noreferrer noopener">Peter Schiff Says A President Shouldn&#8217;t &#8216;Sell White House Tours&#8217; And Pocket The Proceeds As Trump Prepares To Have Dinner With Memecoin Holders</a></li>
</ul>
Image: Shutterstock

Global

Movers

President Trump Approves US Steel, Nippon Steel Partnership

General

MSBI

Midland States Bancorp Receives Notice Of Deficiency From Nasdaq Regarding Delayed Filing Of Quarterly Report On Form 10-Q

Bicara Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) shares are trading lower Friday following the release of updated interim data from its Phase 1/1b trial of ficerafusp alfa in combination with pembrolizumab for patients with recurrent or metastatic head and <a href="https://www.benzinga.com/pressreleases/25/05/g45576170/bicara-therapeutics-announces-publication-of-an-abstract-with-updated-interim-data-from-phase-11b-">neck squamous cell carcinoma. </a>
What To know: The results were posted ahead of the company's upcoming oral presentation at the 2025 ASCO Annual Meeting.
The data showed a 64% objective response rate in HPV-negative patients, with 21% achieving complete responses. While median overall survival has not yet been reached, the current estimate exceeds 20 months. Median progression-free survival was reported at 9.8 months and the 12-month overall survival rate stood at 61%.
Despite these signals, investor reaction was negative due to concerns about the lack of clarity around long-term durability and the relatively small sample size. The company reported that the trial remains ongoing and the full data will be discussed during a conference call on June 1.
Ficerafusp alfa, a bifunctional antibody targeting both EGFR and TGF-β, is intended to improve tumor penetration and response in solid tumors. While Bicara emphasized encouraging signals in HPV-negative patients, who generally face worse outcomes, the market appeared focused on the uncertainty tied to long-term efficacy and the need for more mature survival data.
BCAX Price Action: Bicara shares closed down Friday 40.80% at $9.27, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45592743/stocks-bitcoin-fall-on-trumps-tariff-threats-gold-rallies-whats-driving-markets-friday">Stocks, Bitcoin Fall On Trump&#8217;s Tariff Threats, Gold Rallies: What&#8217;s Driving Markets Friday? </a></li>
</ul>
Image Via Shutterstock.

Biotech

Health Care

BCAX

Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 10 years by 1.16% on an annualized basis producing an average annual return of 11.71%. Currently, Thermo Fisher Scientific has a market capitalization of $148.51 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 10 years ago, it would be worth $3,005.27 today based on a price of $393.66 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748033110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today

NOTE

FiscalNote Holdings  Files For Resale Of Up To 12.5M Shares Of Class A Common Stock By The Selling Stockholders

LTBR

Lightbridge Files For Mixed Shelf Of Up To $150M

Ardent Health Partners, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARDT#NYSE">ARDT</a>) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that its board of directors voted to change the Company's name to Ardent Health, Inc., effective June 3, 2025. The updated name aligns the Company's legal name with its practice of referring to the organization as "Ardent Health" in its communications, ensuring a clear and consistent brand identity.
The name change will have no impact on Ardent Health's trading symbol on the New York Stock Exchange, its CUSIP number, nor the rights of its stockholders. Ardent Health anticipates that its common stock will begin trading under its updated name on June 3, 2025.

ARDT

Ardent Health Partners Changes Name To Ardent Health Inc., Effective June 3, 2025

CAPT

Captivision Receives Nasdaq Notice Regarding Delayed Annual Report On Form 20-F

VIOT

Viomi Technology Receives NASDAQ Letter Regarding Late Filing of Form 20-F

Our money habits operate in the background, but they influence our long-term wealth. While adopting good money habits like saving and investing can be beneficial, there are also a bunch of bad money habits that you should avoid.
Financial guru Vincent Chan recently laid out <a href="https://www.tiktok.com/@vincentchanco/video/7505012156946074912?lang=en">five bad money habits</a> that keep people poor. These habits result in fewer people saving money and not having enough when they approach retirement. Chan outlines the dire nature of the situation while presenting some solutions.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
"The average savings rate in the U.S. is 4.6%," Chan explains.
Make sure you are avoiding these red flags as you work toward your long-term financial goals.
<h2 class="wp-block-heading">Most People Spend First And Save What's Left Over</h2>
Chan starts the list by describing how most people manage their money. People are usually inclined to spend money and then view saving as an afterthought. This mentality can lead to dangerous credit card debt and shrink your nest egg.&nbsp;
Chan recommends that you approach your finances with the 80/20 rule. You should save at least 20% of your money and spend the remaining 80% on necessities and discretionary items. However, you can gradually boost your savings rate above 20% if you find yourself in a position to do so.
Reaching 80/20 will require that you cut back on some expenses. You may have to abandon unused subscriptions and take a closer look at how you spend money. Avoiding impulsive spending and establishing a budget can help you stick with the 80/20 rule.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">Not Investing Early Enough</h2>
Warren Buffett made 99% of his wealth after his 50th birthday. Chan brings up this detail while encouraging people to invest early and often.
Compound growth can work wonders and move you closer to your goals than earning a salary and stashing your money in a checking account. While bank accounts have their value, it's important to regularly invest your money into assets like ETFs and mutual funds. Real estate is another viable option, but it can take some time before you have enough capital to invest.&nbsp;
<h2 class="wp-block-heading">Letting Credit Card Debt Build</h2>
Compound growth doesn't only work for investments. It also applies to credit card debt, but if you let your lingering balance compound for too long, it can put you in a tough financial position.
To remedy this, Chan recommends only using your credit card for purchases if you have enough cash to cover them. You shouldn't carry a balance at the end of each month. Instead, you should pay it in full.&nbsp;
If you are not in a position to pay off your balance each month, make sure it's getting smaller at the end of each month. Don't let credit card debt grow even more than it already has. If you let it grow too much, it can become unmanageable and lead to bankruptcy.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
<h2 class="wp-block-heading">Not Tracking Your Money</h2>
Review your monthly credit card statements and keep a spreadsheet that details your monthly income and expenses. Chan says that it's a big mistake not to know where your money is going.
By monitoring your finances, you can discover new opportunities to save money. Once you set up the systems, it's very easy to stay on top of where your money goes.
<h2 class="wp-block-heading">Not Saving Enough Money</h2>
Most people don't save enough money in the U.S., especially with the average savings rate hovering at 4.6%. You can cut expenses to boost your savings right away, but you will eventually have to prioritize income growth.&nbsp;
Someone who is only saving 4.6% might be able to get to a 5% to 7% savings rate with a few changes to their budget. However, you will only get to a more desirable savings rate that is above 20% if you increase your earnings. You can grow your income by asking for a raise, job hopping, working more hours, or picking up a side hustle.
Read Next:
<ul class="wp-block-list">
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Vincent Chan Reveals The Five Money Habits That Keep People Poor: 'The Average Savings Rate In The U.S. Is 4.6%'

Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) has outperformed the market over the past 15 years by 6.7% on an annualized basis producing an average annual return of 18.58%. Currently, Lennox Intl has a market capitalization of $20.13 billion. 
Buying $100 In LII: If an investor had bought $100 of LII stock 15 years ago, it would be worth $1,267.40 today based on a price of $567.16 for LII at the time of writing.
<h3>Lennox Intl's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748032213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

PRTA

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

TNDM

Tandem Diabetes Care Enters Settlement Agreement With Roche Entities; Settlement Resolves Disputes Related To T:Slim X2 Pump Patents; To Pay Roche $36M Over Five Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 25.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 21.62% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 17.11% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 8.75% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 6.06% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 5.35% at $0.50</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed up 4.13% at $1.24</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 3.69% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 3.45% at $0.15</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 65.00% at $0.0007</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 42.86% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 9.14% at $0.88</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 6.76% at $7.40</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 6.62% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 6.28% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 5.70% at $1.83</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 4.94% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 4.22% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 4.15% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 3.24% at $0.66</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 3.23% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed down 3.21% at $1.55</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNTMF

CRBP

CRLBF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

CXXIF

FFNTF

FUAPF

GNLN

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

MRMD

NWVCF

RMHB

RSSFF

SOLCF

XXII

Marijuana Stock Movers For May 23, 2025

Just as Wall Street seemed as though a sense of stability was finally seeping into 2025, President Trump served a timely reminder that tariff uncertainty will continue to drive market volatility. 
The President announced that he would be "recommending" sweeping 50% tariffs on all European Union imports, due to start on June 1, as a result of a perceived lack of progress in trade negotiations with the bloc. 
Trump elaborated that factors like the EU's trade barriers, VAT taxes, corporate penalties, non-monetary trade barriers, and lawsuits against US firms had contributed to an annual trade deficit exceeding $250 billion, which was labeled "totally unacceptable."
European benchmarks <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45585283/trump-tariff-threat-hits-europe-stocks-sink-as-50-duties-loom">bore the brunt</a> of the President's tariff threat, with the Euro STOXX 50 index tumbling 3% while Italy's FTSE MIB was the worst-affected national index, falling 2.9%.
However, all eyes are now on the S&amp;P 500 and how US markets will respond, just a matter of weeks after the US and China's escalating trade war briefly sank the index before a climbdown restored a measure of investor confidence.&nbsp;
The shock of the announcement triggered a 1.62% decline in the index while investors struggled with the severity of the President's threats.&nbsp;
Worryingly for the tech-heavy S&amp;P 500, Trump also took aim at Apple by suggesting that iPhones should be manufactured in the United States or else the product will be subject to a 25% tariff.&nbsp;
At a time when markets have been recovering following the announcement of a 90-day delay to the United States' reciprocal tariffs announced in April, as well as a subsequent delay to the escalated tariffs on Chinese imports, Trump's hard stance on the European Union and tech imports serves as a timely reminder that Wall Street needs to become accustomed to tariff uncertainty in 2025.&nbsp;
<h2 class="wp-block-heading">An Index in Flux</h2>
Forecasts for the S&amp;P 500 have changed dramatically throughout different stages of the year. Despite trading more than 15% lower between January 1 and April 8, 2025, the index briefly turned positive for the year in mid-May before losing momentum once again.&nbsp;
Just hours before Trump's announcements, Capital Economics raised its forecast for the S&amp;P 500 to 7,000 by the end of 2026, citing the easing of trade tensions and improved market conditions as a core reason for the upturn in confidence. 
This positive sentiment was echoed by Sonu Varghese, a global macro strategist with Carson Wealth, <a href="https://www.spglobal.com/market-intelligence/en/news-insights/articles/2025/5/sp-500-valuations-stumble-on-tariff-uncertainty-89099352">who suggested</a> that there was ‘too much uncertainty,' but that the Trump administration's recent pullbacks from their initial tariff salvo were a cause for cautious optimism.&nbsp;
This turnaround in sentiment has been astonishing when looking back at April's tariff-related downturn. In the midst of Trump's tariff uncertainty, the Economy Forecast Agency updated its expectations for the S&amp;P 500 to an annual close of 4,379. Looking further ahead to the end of 2026, expectations appeared a little rosier at 5,708. 
These major expectation shifts from economists show that Wall Street is struggling to keep up with the unpredictability of the Trump administration and that the S&amp;P 500 is likely to be more vulnerable to unexpected investor sentiment changes based on the President's use of social media to share frequent policy updates.&nbsp;
<h2 class="wp-block-heading">Disrupting the Magnificent Seven</h2>
It would be a challenge to assess which of Trump's announcements &#8211; on EU tariffs and levies on Apple product imports &#8211; has the most significant ramifications for the S&amp;P 500. 
The Magnificent Seven, a collective of large-cap tech stocks consisting of Apple, Amazon, Microsoft, Google parent Alphabet, Nvidia, Meta, and Tesla, accounts for more than one-third of the total market capitalization of the S&amp;P 500. This means that tariff disruption affecting these stocks can severely impact the performance of the index as a whole. 
Upon claiming that Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) would be subject to a <a href="https://www.bbc.co.uk/news/articles/cgr5xrygzk5o">25% import tariff</a> if iPhones continue to be manufactured outside of the United States, the tech giant's stock slipped 3.72% at the beginning of trading on Friday, 23 May.&nbsp;
Apple had been resorting to airlifting as much as 600 tons of iPhones from India as a means of bypassing tariffs. However, Trump's ambitions for American firms are to shift manufacturing to the United States, helping to boost industry.&nbsp;
Should the President adopt a similar stance to US tech leaders and large-cap firms, we could see severe disruption throughout many key market players and their supply chains.&nbsp;
Given that manufacturing in China, for instance, is significantly lower in cost compared to the United States due to factors like cheaper labour, smaller energy costs, and stronger logistics, the shift to US-based manufacturing could be a significant disruptive force should domestic infrastructure struggle to keep up.&nbsp;
<h2 class="wp-block-heading">Adapting to Uncertainty</h2>
2025 is fast becoming a year of extreme market uncertainty due to the unpredictability of tariffs and the willingness of the President to share prospective policy shifts on social media.&nbsp;
For investors, it's essential to keep a level head when dealing with volatility in the S&amp;P 500 and to avoid taking rash decisions by withdrawing investments or buying into speculative stocks on a whim.&nbsp;
We're likely to learn a lot about Trump's stance on tariffs as the initial 90-day tariff delay to April's reciprocal tariffs ends on July 8. Until then, adopting a more cautious strategy could be the most measured strategy on Wall Street.
Disclosure:&nbsp;On the date of publication, Dmytro Spilka did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer. Dmytro Spilka does not intend to make a trade in any of the securities mentioned above in the next 72 hours.

Equities

Government

Regulations

Broad U.S. Equity ETFs

Opinion

AAPL

Trump's Trade Spat With Europe And Apple Revives Tariff Risks For S&P 500

While municipal bond inflows swell and tax season tastes like bitter almonds, Vanguard is dishing up new relief for income-hungry investors, once more with two <a href="https://www.benzinga.com/etfs">brand-new low-cost ETFs</a> designed for long-term strategy and local benefit.
The company launched today the Vanguard Long-Term Tax-Exempt Bond ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/VTEL#BATS">VTEL</a>) and the Vanguard New York Tax-Exempt Bond ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MUNY#BATS">MUNY</a>), bringing its muni ETF lineup to six and its entire municipal lineup (which includes six index ETFs, two active ETFs, 12 active mutual funds, one index mutual fund, and three money market funds) to 24.
Also Read: <a href="https://www.benzinga.com/25/05/45594832/not-all-bitcoin-etfs-are-created-equal-heres-how-structure-shapes-risk-returns-and-taxes">Not All Bitcoin ETFs Are Created Equal: Here&#8217;s How Structure Shapes Risk, Returns, And Taxes</a>
VTEL provides investors with exposure to longer-term municipal bonds, a good wager for those expecting rate reductions or wanting to fix returns. MUNY targets debt issued by New York, providing a concentrated defense for residents who want to limit both state and federal tax nibbles.
Both ETFs have a low cost of 0.09%, in line with Vanguard&#8217;s promise of quality without the cost. Both funds are passively managed, providing investors with a no-frills, index-based strategy in an otherwise complicated corner of the bond market.
The timing isn't coincidental. Investors have poured into municipal bond ETFs this year, with the flagship Vanguard Tax-Exempt Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEB#NYSE">VTEB</a>) alone pulling in $3.48 billion in net flows over the past year, according to FactSet data as of May 20. That surge underscores growing demand for tax-aware, duration-managed products amid uncertainty around rates and inflation.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/05/45577673/strategy-shares-rolls-the-dice-with-monopoly-etf-for-market-giants">Strategy Shares Rolls The Dice With Monopoly ETF For Market Giants</a>
Vanguard&#8217;s newest additions complete a strategy that more and more serves the &#8220;do-it-yourself allocator.&#8221; With national muni exposure through VTEB and Vanguard Short-Term Tax-Exempt Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTES#NYSE">VTES</a>), state-specific accessibility through Vanguard California Tax-Exempt Bond ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/VTEC#BATS">VTEC</a>) and now MUNY (New York), and longer-duration flexibility through VTEL, advisors and individuals can now construct more thoughtful municipal ladders without leaving the Vanguard world.
For a company more famous for steady fingers than glitzy headlines, Vanguard&#8217;s muni ETF movements might appear subtle, but in a yield-starved environment replete with tax pitfalls, that&#8217;s precisely the sort of low-key plan investors are on the hunt for.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45593231/trump-sparks-uranium-frenzy-nuclear-etfs-see-explosive-gains">Trump Sparks Uranium Frenzy: Nuclear ETFs See Explosive Gains</a></li>
</ul>
Photo: Zakharchuk via Shutterstock

Bonds

New ETFs

ETFs

Vanguard New York Tax-Exempt Bond ETF Vanguard New York Tax-Exempt Bond ETF

MUNY

VTEB

VTEC

Vanguard Tax-Managed Funds Vanguard Long-Term Tax-Exempt Bond ETF

VTEL

Vanguard Wellington Fund Vanguard Short-Term Tax Exempt Bond ETF

VTES

Vanguard Doubles Down On Munis With Two New ETFs — Just In Time For Tax-Weary Investors

Middlesex Water Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSEX#NASDAQ">MSEX</a>), a provider of life-sustaining water and wastewater utility services, announced that its Board of Directors has named Nadine Leslie as Chair of the Board. Leslie, who currently serves as President and Chief Executive Officer, succeeds Dennis W. Doll, who retired from the Board following a 20-year tenure with the company.
The Board also named Amy Mansue to serve as its Lead Independent Director, a role established to further support the Board's independence and strengthen governance oversight.

Management

MSEX

Middlesex Water Company Names President And CEO Nadine Leslie As Chair Of The Board, Succeeding Dennis W. Doll

Jayud Global Logistics Receives Nasdaq Letter Regarding Minimum Bid Price Deficiency

Plus Therapeutics, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) (the "Company") today announced it received a delinquency notification letter from Nasdaq on May 21, 2025, which indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the "Quarterly Report"). The Nasdaq Listing Rule requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the "SEC"). This notification has no immediate effect on the listing of the Company's securities on Nasdaq.
Nasdaq has informed the Company that it must submit a plan to regain compliance with respect to the filing requirement by July 21, 2025. If the plan is accepted, Nasdaq can grant an exception of up to 180 calendar dates from the due date of the filing, or until November 17, 2025, to regain compliance.
The Company is working diligently to file the Quarterly Report as promptly as practical, and expects to return to a normal filing cadence for the remainder of 2025.

PSTV

Plus Therapeutics Receives Nasdaq Delinquency Notice Over Late Form 10-Q Submission

Transaction Expected to Close in Q3 2025
SatixFy Communications Ltd. ("SatixFy" or the "Company") (NYSE:<a href="https://www.benzinga.com/stock/SATX#NYSE">SATX</a>), today announced that at a special meeting of shareholders (the "Meeting") on May 23, 2025, holders of the majority of outstanding ordinary shares of SatixFy voted to approve the Agreement and Plan of Merger (the "Merger Agreement") with MDA Space Ltd. ("MDA Space"), as amended and announced on May 20, 2025, pursuant to which MDA Space agreed to acquire SatixFy in an all-cash transaction (the "Merger").
Over 99% of the Company's outstanding ordinary shares that were voted at the Meeting in person or by proxy were voted in favor of the adoption of the Merger Agreement and the Merger.

SatixFy Communications Ltd. Ordinary Share

SATX

SatixFy Shareholders Approve Proposed Acquisition By MDA Space; Transaction Expected To Close In Q3 2025

Press Releases

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

VIGL Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Vigil Neuroscience, Inc. is Fair to Shareholders

Shareholder Alert: The Ademi Firm Investigates Whether Vigil Neuroscience Inc. Is Obtaining a Fair Price for Its Public Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VIGL, TXNM, SVT, PTIX on Behalf of Shareholders

Navitas (NASDAQ: NVTS) Surges on NVIDIA Deal – SNYR, VIGL, XAGE Lead $2 Stock Watch Now, More Inside

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

Comments

Vigil Neuroscience

Vigil Neuroscience (VIGL) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌